Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 61 of the 63 references it cites were found in a registry or an index.

A large meta-analysis establishes the role of MRD negativity in long-term survival outcomes in patients with multiple myeloma

Open access

Abstract

The prognostic value of minimal residual disease (MRD) for progression-free survival (PFS) and overall survival (OS) was evaluated in a large cohort of patients with multiple myeloma (MM) using a systematic literature review and meta-analysis. Medline and EMBASE databases were searched for articles published up to 8 June 2019, with no date limit on the indexed database. Clinical end points stratified by MRD status (positive or negative) were extracted, including hazard ratios (HRs) on PFS and OS, P values, and confidence intervals (CIs). HRs were estimated based on reconstructed patient-level data from published Kaplan-Meier curves. Forty-four eligible studies with PFS data from 8098 patients, and 23 studies with OS data from 4297 patients were identified to assess the association between MRD status and survival outcomes. Compared with MRD positivity, achieving MRD negativity improved PFS (HR, 0.33; 95% CI, 0.29-0.37; P < .001) and OS (HR, 0.45; 95% CI, 0.39-0.51; P < .001). MRD negativity was associated with significantly improved survival outcomes regardless of disease setting (newly diagnosed or relapsed/refractory MM), MRD sensitivity thresholds, cytogenetic risk, method of MRD assessment, depth of clinical response at the time of MRD measurement, and MRD assessment premaintenance and 12 months after start of maintenance therapy. The strong prognostic value of MRD negativity and its association with favorable outcomes in various disease and treatment settings sets the stage to adopt MRD as a treatment end point, including development of therapeutic strategies. This large meta-analysis confirms the utility of MRD as a relevant surrogate for PFS and OS in MM.

Overview

Integrity signals

Registry

Crossref · 10.1182/bloodadvances.2020002827

Cites

61 of 61 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

We couldn’t retrieve this paper’s full text, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 63 references

Research works printed but not linked: 4

  1. Solovev, 2017, Maintenance therapy with bortezomib in patients with multiple myeloma (MM) after ASCT and minimal residual disease (MRD), Haematologica, 102, E1295
  2. Popat, 2017, Outcomes of stratification to ASCT or not based on depth of response: results of a phase 2 trial assessing the impact of minimal residual disease (MRD) in multiple myeloma patients with deferred ASCT (PADIMAC), Blood, 130, 1864
  3. Oliva, 2017, Minimal residual disease by multiparameter cytometry in transplant eligible patients with newly diagnosed multiple myeloma: results from the EMN02/HO95 phase 3 trial, Haematologica, 102, S102
  4. Austin, 2018, Sustained MRD negativity at 12 months post-ASCT predicts outcomes for myeloma patients: a real world study, EHA Library, 215626, 2018

Cited by

See all 431

Metadata

Authors
Munshi, N. C., Avet-Loiseau, H., Anderson, K. C., Neri, P., Paiva, B., Samur, M., Dimopoulos, M., Kulakova, M., Lam, A., Hashim, M., He, J., Heeg, B., Ukropec, J., Vermeulen, J., Cote, S., & Bahlis, N.
Affiliations
  • Harvard University (US)
  • Unité de Génomique du Myélome, Institut Universitaire du Cancer de Toulouse (IUC-T) Oncopole, Toulouse, France;
  • University of Calgary (CA)
  • Navarre Institute of Health Research (ES)
  • National and Kapodistrian University of Athens (GR)
  • Ingress Health, Rotterdam, The Netherlands;
  • Janssen Global Services, LLC, Raritan, NJ; and
  • Janssen Global Medical Affairs, Horsham, PA
Venue
Blood Advances
Published
2020-12-07
Volume
4
Issue
23
Pages
5988-5999
ISSN
  • 2473-9529 (ISSN-L)
  • 2473-9537
OpenAlex
W3111394247
Cited by
431
References
63
Citations by year
2026: 63 · 2025: 88 · 2024: 88 · 2023: 79 · 2022: 65 · 2021: 46
FWCI
7.45
Type
journal article
Language
en
Open access
Licence
cc-by-nc-nd
Locations
  • Blood Advances (publishedVersion, cc-by-nc-nd)
  • PubMed Central (publishedVersion)
  • PubMed (publishedVersion)
Funders
  • U.S. Department of Veterans Affairs (I01 BX000158)
  • National Institutes of Health (PO1-155258, P50-100707)
  • National Cancer Institute (P50CA100707, P01CA155258)
  • Cilag
Topics
  • Health Sciences › Medicine › Hematology › Multiple Myeloma Research and Treatments
  • Health Sciences › Medicine › Hematology › Chronic Lymphocytic Leukemia Research
  • Health Sciences › Medicine › Clinical Neurology › Multiple Sclerosis Research Studies
Keywords
multiple myeloma, minimal residual disease, MRD negativity, progression-free survival, overall survival, prognostic factors, relapsed/refractory multiple myeloma, newly diagnosed multiple myeloma, maintenance therapy, cytogenetic risk
MeSH terms
Cytogenetics, Humans, Multiple Myeloma, Prognosis, Treatment Outcome, Neoplasm, Residual

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: A large meta-analysis establishes the role of MRD negativity in long-term survival outcomes in patients with multiple myeloma. https://app.cochat.ai/papers/10.1182/bloodadvances.2020002827
The paper
Munshi, N. C., Avet-Loiseau, H., Anderson, K. C., Neri, P., Paiva, B., Samur, M., Dimopoulos, M., Kulakova, M., Lam, A., Hashim, M., He, J., Heeg, B., Ukropec, J., Vermeulen, J., Cote, S., & Bahlis, N. (2020). A large meta-analysis establishes the role of MRD negativity in long-term survival outcomes in patients with multiple myeloma. Blood Advances. https://doi.org/10.1182/bloodadvances.2020002827

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.